Cognitive Boosts in Migraine: Anti-CGRP and Botox Benefits

Research Summary

A study published in Cephalalgia explores the cognitive benefits of anti-CGRP monoclonal antibodies (mAbs) and botulinum toxin (BoNT) in migraine patients. Researchers examined 100 patients with episodic or chronic migraine, focusing on cognitive changes after three to six months of treatment. The study found that 52% of participants were responders, defined by a significant reduction in headache days. Among responders, improvements in executive functions, such as working memory and attention, were noted regardless of the treatment type. However, no significant differences were observed in other cognitive domains. Further research is needed to understand the long-term effects and underlying mechanisms.

Study Details

📄 Title: Beyond headache: Cognitive improvement in patients with migraine responding to anti-CGRP monoclonal antibodies or botulinum toxin.

👥 Research Team: Martins IP et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2026 Jun

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.